Abstract
The APA, through its expanded criteria for diagnosing mental disorders, and academic psychiatry, through its legitimization of the expanded boundaries and its reports of the efficacy of drugs for these patient groups, helped create a much larger market for psychiatric medications. Societal spending on psychiatric drugs increased from approximately $800 million in 1987 to more than $35 billion in 2010. But this was a market built on a compromised scientific foundation, and time and again, the field struggled to maintain societal belief in these medications, particularly in the face of study results that raised questions about their merits over longer periods of timeāone year and beyond.
People usually remain unaware that they are acting immorally as the result of a conflict of interest.
āPaul Thagard, 20071
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Notes
P. Thagard. āThe moral psychology of conflicts of interest.ā J Applied Philosophy 24 (2007): 367ā80.
J. Richters. āNIMH Collaborative Multisite Multimodal Treatment Study of Children with ADHD.ā J Am Acad Child Adolesc Psychiatry 34 (1995): 987ā1000.
The MTA Cooperative Group. āA 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder.ā Arch Gen Psychiatry 56 (1999): 1073ā86.
P. Jensen. ā3-year follow-up of the NIMH MTA Study.ā J Am Acad Child Adolesc Psychiatry 46 (2007): 989ā1002.
B. Molina. āDelinquent behavior and emerging substance use in the MTA at 36 months.ā J Am Acad Child Adolesc Psychiatry 46 (2007): 1028ā40.
J. Swanson. āEvidence, interpretation and qualification from multiple reports of long-term outcomes in the multimodal treatment study of children with ADHD Part II.ā J Attention Disorders 12 (2008): 15ā43.
B. Molina. āMTA at 8 years.ā J Am Acad Child Adolesc Psychiatry 48 (2009): 484ā500.
Western Australian Department of Health. āRaine ADHD study: Long-term outcomes associated with stimulant medication in the treatment of ADHD children,ā 2009. Accessed at: www.health.wa.gov.au/publications/documents/MICADHD_Raine_ADHD_study_report_022010.pdf/publications/documents/MICADHD_Raine_ADHD_study_report_022010.pdf
J. Currie. āDo stimulant medications improve educational and behavioral outcomes for children with ADHD?ā NBER working paper 19105, June 2013.
M. Posternak. āA reevaluation of the exclusion criteria used in antidepressant efficacy trials.ā Am J Psychiatry 159 (2002): 191ā200.
J. Rush. āOne-year clinical outcomes of depressed public sector outpatients.ā Biol Psychiatry 56 (2004): 46ā53.
Hypericum depression trial study group. āEffect of Hypericum perforatum (St. Johnās Wort) in major depressive disorder.ā JAMA 287 (2002): 1807ā14.
M. Babyak. āExercise treatment for major depression.ā Psychosom Med 62 (2000): 633ā38.
NIMH. āQuestions and answers about the NIMH Sequenced Treatment Alternatives to Relieve Depression (STARāD) StudyāBackground.ā Press release, January 2006.
J. Rush. āSequenced treatment alternatives to relieve depression (STARāD): rationale and design.ā Controlled Clinical Trials 25 (2004): 119ā42.
M. Trivedi. āEvaluation of outcomes with Citalopram for depression using measurement-based care in STARāD.ā Am J Psychiatry 163 (2006): 28ā40.
A. Rush. āBuproprion-SR, sertraline, or venlafaxine-XR after failures of SSRIs for depression.ā NEJM 354 (2006): 1231ā42.
Also see M. Trivedi. āMedication augmentation after the failure of SSRIs for depression.ā NEJM 354 (2006): 1243ā52.
A. Rush. āAcute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STARāD report.ā Am J Psychiatry 163 (2006): 1905ā17.
E. Pigott. āAdding Fiction to Fiction,ā blog post on madinamerica.com, April 10, 2011.
H. Pigott. āEfficacy and effectiveness of antidepressants.ā Psychother Psychosom 79 (2010): 267ā79.
Also see H. Pigott. āSTARāD: A tale and trail of bias.ā Ethical Human Psychology and Psychiatry 13 (2011): 6ā28.
A. Rush. āAcute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STARāD report.ā Am J Psychiatry 163 (2006): 1905ā17.
L. Pratt. āAntidepressant use in persons age 12 and over: United States 2005ā2008.ā National Center for Health Statistics Data Brief # 76, October 2011.
J. Jureidini. āEfficacy and safety of antidepressants for children and adolescents.ā Br Med J 328 (2004): 879ā83.
C. Whittington. āSelective serotonin reuptake inhibitors in childhood depression.ā Lancet 363 (2004): 1341ā5.
TADS team. āFluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression.ā JAMA 292 (2004): 807ā20.
G. Emslie. āTreatment for adolescents with depression study (TADS): Safety results.ā J Am Acad Child Adolesc Psychiatry 45 (2006): 1440ā55.
TADS team. āThe treatment for adolescents with depression study (TADS): Long-term effectiveness and safety outcomes.ā Arch Gen Psychiatry 64 (2007): 1132ā44.
B. Kennard. āAssessment of safety and long-term outcomes of initial treatment with placebo in TADS.ā Am J Psychiatry 166 (2009): 337ā44.
B. Vitiello. āSuicidal events in the treatment for adolescents with depression study (TADS).ā J Clin Psychiatry 70 (2009): 741ā7.
Copyright information
Ā© 2015 Robert Whitaker and Lisa Cosgrove
About this chapter
Cite this chapter
Whitaker, R., Cosgrove, L. (2015). Protecting the Market. In: Psychiatry Under the Influence. Palgrave Macmillan, New York. https://doi.org/10.1057/9781137516022_7
Download citation
DOI: https://doi.org/10.1057/9781137516022_7
Publisher Name: Palgrave Macmillan, New York
Print ISBN: 978-1-349-50598-2
Online ISBN: 978-1-137-51602-2
eBook Packages: Palgrave Social Sciences CollectionSocial Sciences (R0)